Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
| Business Activity | PASS |
| Debt Ratio (0.31%) | PASS |
| Cash Ratio (0.82%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-11 | -0.26 | Pending | -- |
| 2026-05-13 | -0.28 | -0.26 | +5.5% |
| 2026-02-26 | -0.27 | -0.27 | +0.5% |
| 2025-11-13 | -0.28 | -0.27 | +4.3% |
| 2025-08-12 | -0.34 | -0.29 | +15.8% |
| 2025-05-13 | -0.38 | -0.32 | +15.7% |
| 2025-03-05 | -0.42 | -0.44 | -3.8% |
| 2024-11-12 | -0.41 | -0.40 | +3.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.3M | -$31.2M | -$30.1M | — | -$33.0M | -0.26 |
| 2025-12-31 | $1.4M | -$32.4M | -$31.7M | — | -$34.7M | -0.27 |
| 2025-09-30 | $1.7M | -$32.2M | -$31.5M | — | -$34.7M | -0.27 |
| 2025-06-30 | $1.9M | -$34.1M | -$33.7M | — | -$37.0M | -0.29 |
| 2025-03-31 | $1.6M | -$37.6M | -$37.9M | — | -$41.3M | -0.32 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-20 | TAHL CINDY R | Officer | 25,590 | $48.1K |
| 2026-05-20 | VALAMEHR BAHRAM | Chief Executive Officer | 28,946 | $54.5K |
| 2026-05-06 | TAHL CINDY R | Officer | 166,664 | $208.0K |
| 2026-05-05 | RASTETTER WILLIAM H | Director | 25,000 | $42.2K |
| 2026-05-05 | EPSTEIN ROBERT S | Director | 25,000 | $42.2K |
| 2026-01-15 | TAHL CINDY R | Officer | 100,000 | -- |
| 2026-01-15 | VALAMEHR BAHRAM | Chief Executive Officer | 335,000 | -- |
| 2026-01-15 | ADAWI KAMAL | Chief Financial Officer | 25,000 | -- |
| 2026-01-09 | TAHL CINDY R | Officer | 10,589 | $11.3K |
| 2026-01-09 | VALAMEHR BAHRAM | Chief Executive Officer | 5,190 | $5.6K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Redmile Group, LLC | 12.9M | $29.0M | 0.1% |
| Blackrock Inc. | 10.1M | $22.7M | 0.1% |
| Vanguard Capital Management LLC | 4.2M | $9.4M | 0.0% |
| Vanguard Portfolio Management LLC | 4.1M | $9.3M | 0.0% |
| Acadian Asset Management. LLC | 4.1M | $9.3M | 0.0% |
| Two Sigma Investments, LP | 3.5M | $7.8M | 0.0% |
| Johnson & Johnson | 3.4M | $7.6M | 0.0% |
| AQR Capital Management, LLC | 3.0M | $6.8M | 0.0% |
| Renaissance Technologies, LLC | 3.0M | $6.7M | 0.0% |
| Geode Capital Management, LLC | 2.6M | $5.8M | 0.0% |
$164.2M
1.46
2.136
8
$6.3M
$76.8M
2.08
8.90
0.1%
161
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.26 | Pending | — |
| 2026-05-13 | $-0.28 | $-0.26 | +5.5% |
| 2026-02-26 | $-0.27 | $-0.27 | +0.5% |
| 2025-11-13 | $-0.28 | $-0.27 | +4.3% |
| 2025-08-12 | $-0.34 | $-0.29 | +15.8% |
| 2025-05-13 | $-0.38 | $-0.32 | +15.7% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($5.41, 9 analysts) | |||
| 10 | $21.35 | +$32.80 (153%) | 10.2R |
| 50 | $106.75 | +$164.00 (153%) | 10.2R |
| 100 | $213.50 | +$328.00 (153%) | 10.2R |
- High beta (2.14) — amplifies market moves by 2.14x
- Elevated short interest (8.90 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ARKG | 0.484 |
| ALLO | 0.463 |
| RXRX | 0.444 |
| CRSP | 0.442 |
| BEAM | 0.420 |
| Ticker | Correlation |
|---|---|
| 0857.HK | -0.145 |
| SEEF.BH | -0.144 |
| TREVQ | -0.128 |
| STO.AX | -0.128 |
| 4578.T | -0.126 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.